Breast Cancer Clinical Trials

Showing 3001-3020 of 5,597 trials

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596

This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.

Metastatic Breast Cancer

University of Maryland, Baltimore2 participantsStarted Jan 2014

Baltimore, Maryland, United States

UNKNOWN

Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer

NCT05394194

We aim to compare three different radiation delivery techniques, namely three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiotherapy (IMRT) and volumetric modulated radiation therapy (VMAT) in left-sided early breast cancer patients.

Breast Cancer

Sohag University30 participantsStarted Jul 2022

WITHDRAWNPhase 2

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

NCT04351230

This phase II trial studies how well T-DMI with or without abemaciclib works for the treatment of HER2-positive breast cancer that has spread to other places in the body (metastatic). T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers DM1 to kill them. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and abemaciclib may work better in treating patients with breast cancer compared to T-DM1 alone.

Anatomic Stage IV Breast Cancer AJCC v8HER2 Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more

Academic and Community Cancer Research UnitedStarted Nov 2020

Yuma, Arizona, United States • Jacksonville, Florida, United States • Urbana, Illinois, United States +3 more locations

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Related Searches

Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer

Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

Expanded Access to Veliparib

Effect of Chan-Chuang Qigong With Breathing Meditation on Quality of Life in Patients With Breast Cancer

Micrima MARIA Data Collection for Machine Learning Study

Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

EndoPredict® Extended Endocrine Trial (EXET)

Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

SIGNAL During a COVID-19 Pandemic

An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain

Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer

Integrated Care Pathway in Oncology (PASSION)

Single Fraction Intraoperative Radiotherapy

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate